Journal
EXPERT OPINION ON INVESTIGATIONAL DRUGS
Volume 16, Issue 12, Pages 1895-1908Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1517/13543784.16.12.1895
Keywords
antiangiogenesis; glioma; vascular normalization; vasogenic edema
Categories
Funding
- NCI NIH HHS [P01 CA080124] Funding Source: Medline
Ask authors/readers for more resources
Glioblastomas are highly vascularized and, therefore, antiangiogenic agents are increasingly being explored as therapeutic options. This review summarizes the present data on antiangiogenic agents in glioblastoma treatment. The angiogenic pathway in gliomas and the proposed mechanisms of antiangiogenic agents are reviewed briefly, and details of the drugs in clinical trial are provided. In addition to their effects on blood vessels, these agents also have potent anti-edema effects that may have therapeutic benefit. The review concludes with a discussion of the role of biomarkers and neuroimaging in the assessment of tumor response. Although preliminary studies of these drugs in glioblastoma have been promising, larger prospective trials that include survival as an end point will be required to determine the ultimate utility of this class of agents. it seems likely that a combination of antiangiogenesis agents with other cytotoxic therapies will be required to achieve maximal efficacy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available